Drug Profile
Research programme: gastrointestinal stromal tumour therapeutics - Clovis Oncology/Array BioPharma
Alternative Names: cKIT inhibitor - Clovis Oncology/Array BioPharmaLatest Information Update: 20 Sep 2023
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Clovis Oncology
- Class Small molecules
- Mechanism of Action Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal stromal tumours
Most Recent Events
- 20 Sep 2023 Discontinued for Gastrointestinal stromal tumours in USA (PO)
- 30 Jul 2019 Array BioPharma has been acquired by Pfizer
- 16 Jul 2016 No recent reports of development identified for research development in Gastrointestinal-stromal-tumours in USA (PO)